Repligen's major customers
Pfizer accounted for 10% of Repligen's revenue in FY 2021, about the same as 11% a year earlier.
Get an email when Repligen's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Major customers of Repligen
Customers that Repligen named in its annual report as 10% or more of revenue. A missing year means the customer was below that line or not named.
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| PfizerPFE | 10% | from 11% | 2 years | FY 2021 · filed 22 Feb 2024 |
Formerly disclosed
| Customer | Share of revenue | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Bristol Myers SquibbBMY | 27% | last FY 2013 | 2 years | FY 2013 · filed 17 Mar 2015 |
| Cytiva | 12% | last FY 2019 | 2 years | FY 2019 · filed 17 Feb 2022 |
| General Electric Healthcare | 12% | last FY 2019 | 8 years | FY 2019 · filed 26 Feb 2020 |
| Millipore Sigma | 11% | last FY 2020 | 8 years | FY 2020 · filed 22 Feb 2023 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API